Trial Profile
A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan [EXTENSION OF 700060213]
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Voglibose
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Takeda
- 20 Mar 2014 New trial record